

**HAVE YOUR SAY**

Comment on any of our News stories, online.

www.nature.com/news

says Saul, is to put a price on carbon quickly.

A small foray into carbon taxing has already been made in Canada. British Columbia's Liberal provincial government implemented the first major North American carbon tax in July, at a rate of Can\$10 per tonne of CO₂ (or equivalent emissions), rising to Can\$30 per tonne in 2012. The province's plan is also revenue neutral, with companies paying the majority of the tax and individuals receiving most of the credit — including a one-off cheque for Can\$100 earlier this summer that is meant to be spent on creating more environmentally friendly lifestyles.

Earlier this month, more than 60% of 1,000 people polled nationally said that climate change would be important or the most important issue in deciding their vote. Such opinions don't always survive in the polling booth, but constant reminders of the impacts of climate change did influence Conservative-minded Australians to vote out their government in elections last year.

Canadian policy experts see their country lagging behind Europe on climate issues. It could yet catch up. But although Canada's election precedes the one down south, their policies may yet be held back by US decisions. "There's a real danger that we're just going to kind of adopt whatever happens in the United States," says Saul. "Canadian politicians don't like to make a stand if Americans aren't doing the same." ■

Nicola Jones


See Editorial, page 263.

Iran holds AIDS doctors

Iran is under mounting pressure to reveal the whereabouts of two of the nation's HIV researchers, who have been detained without charge since late June.

The brothers, Arash and Kamiar Alaei, have achieved international acclaim for their progressive HIV-prevention programme and were scheduled to speak about it at the 17th International AIDS Conference in Mexico City last month. Both were arrested before leaving the country. The men had collaborated with other scientists around the world, including some in the United States, and are not thought to have been politically active.

Protests in their support were made at the conference. Since then, several human-rights organizations, including Physicians for Human Rights and Amnesty International, have called



Arash Alaei has not been seen since June.

on Iran to abide by its international legal obligations to explain the arrests and allow the men access to lawyers and the right to contest their detention before a judge.

The call has been taken up by several scientific bodies, including the International AIDS Society, the Foundation for AIDS Research and the American Association for the Advancement of Science (AAAS), and thousands of scientists and physicians have signed an online petition at www.iranfreethedocs.org. Barry Bloom, dean of the Harvard School of Public Health in Boston, Massachusetts, has also expressed his "deep concern" over the brothers' detention.

Kamiar, the younger of the brothers, holds a master's degree from the Harvard School of Public Health and was to have resumed doctoral studies at the University of Albany's School of Public Health in New York. Arash, former head of international education and research cooperation at the Iranian National Research Institute of Tuberculosis and Lung Disease, runs a clinic in Tehran.

HIV is a taboo subject in much of the Middle East, including Iran, but the brothers have helped to forge impressive prevention and treatment programmes — the country is now one of the few to distribute condoms and syringes in prisons, for example. ■

Declan Butler

H. ALLAW/KRY/NEWSCOM

Japan fast-tracks stem-cell patent

Kyoto University in Japan has acquired the world's first patent for induced pluripotent stem (iPS) cells. The university paid registration fees for the patent (2008-131577), which is of only limited coverage and applies only in Japan, on 2 September, after it was approved by the Japanese patent office.

Shinya Yamanaka, a stem-cell researcher at the university, created the first iPS cells in 2006 by using four genetic factors to 'reprogram' adult cells from mice into an embryonic-stem-cell-like state. A year later he achieved the same in human cells, publishing the research the same day as a US team led by James Thomson of the University of Wisconsin. Thomson's group used a different set of genetic factors to make its human iPS cells.

iPS cells have the potential to develop into almost any of the body's cell types, and hold great promise in therapy and disease modelling. Kyoto University applied for an international patent (PCT/JP2006/324881) in December 2006. A US patent application is in Yamanaka's name.

Kyoto University expects the international patent to cover iPS cells from all species — "any cell, besides a germ cell, of any type of organism," says Hideya Hayashi of the university's iPS Cell Research and Application office.

The international patent has many claims in it, so it will probably take another year or longer for the various patent offices to process and approve it, says Hayashi. Kyoto University did

not want to wait, so it fast-tracked the Japanese patent application for the most basic claim, covering the "method" of using Yamanaka's four genetic factors to reprogram a cell. "A lot of people were wondering what was happening with these patents. We wanted to make it clear," Hayashi says.

Other claims in the international patent still need to be worked out, especially that covering the product, the iPS cells themselves. It's not certain whether Yamanaka's patents cover iPS cells created by reprogramming with different genetic factors. Itsuki Shimbo, a patent attorney with the Tokyo-based firm Tsubame says it is unclear whether the patent will be able to restrict scientists using other combinations.

Hayashi says the university does not plan to restrict others from doing iPS cell research. Rather, it wants to ensure that people, including Yamanaka, are not restricted by other patents and can freely use iPS cell technology. "We want to remove any potential obstacles to the quick clinical application of iPS technology," Hayashi says. "We are not trying to confine its use."

Shimbo says that Yamanaka's patent might prevent future restrictive iPS patents based on different combinations of genetic factors. "It will be very hard to claim that such a change was truly novel," he says.

The Japanese patent will be valid until 6 December 2026, 20 years from the application date. ■

David Cyranoski